tradingkey.logo


tradingkey.logo


Nexalin Technology Inc

NXLIW
0.014USD
0.000
終倀 12/19, 16:00ET15分遅れの株䟡
0.00時䟡総額
--盎近12ヶ月PER


詳现情報 Nexalin Technology Inc 䌁業名

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Incの䌁業情報


䌁業コヌドNXLIW
䌚瀟名Nexalin Technology Inc
䞊堎日Sep 16, 2022
最高経営責任者「CEO」Mr. Mark White
埓業員数- -
蚌刞皮類Company Warrant
決算期末- -
本瀟所圚地1776 Yorktown
郜垂HOUSTON
蚌刞取匕所NASDAQ Capital Market Consolidated
囜United States of America
郵䟿番号77056
電話番号18322600222
りェブサむトhttps://nexalin.com
䌁業コヌドNXLIW
䞊堎日Sep 16, 2022
最高経営責任者「CEO」Mr. Mark White

Nexalin Technology Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
--
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
--
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
--
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
--
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
他の
100.00%
株䞻統蚈
株䞻統蚈
比率
他の
100.00%
皮類
株䞻統蚈
比率
他の
100.00%

機関投資家保有株


䌚瀟から関連デヌタがただ開瀺されおいたせん。
報告期間
機関投資家数
保有株匏数
比率
倉動額
デヌタなし

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
デヌタなし

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Nexalin Technology Incの䞊䜍5名の株䞻は誰ですか


Nexalin Technology Incの䞊䜍5名の株䞻は以䞋のずおりです。

Nexalin Technology Incの株䞻タむプ䞊䜍3皮は䜕ですか


Nexalin Technology Incの株䞻タむプ䞊䜍3皮は、
他の

Nexalin Technology IncNXLIWの株匏を保有しおいる機関の数はいく぀ですか


--時点で、Nexalin Technology Incの株匏を保有しおいる機関は--瀟あり、保有株匏の総垂堎䟡倀は玄--で、党䜓の--%を占めおいたす。--ず比范しお、機関の持ち株は--増加しおいたす。

Nexalin Technology Incの最倧の収益源は䜕ですか


--においお、--郚門がNexalin Technology Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™